Revolution Medicines, Inc. Common Stock
RVMD
$151.56
-1.41%
Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers, a historically difficult-to-treat genetic driver. The company is a leader in the field, leveraging its proprietary chemical biology platform to create small molecule inhibitors that target the active, GTP-bound state of RAS variants (RAS(ON) Inhibitors). The current investor narrative is overwhelmingly centered on the transformative clinical data for its lead candidate, daraxonrasib, which demonstrated a survival benefit in a Phase 3 pancreatic cancer trial, and the subsequent $2.2 billion capital raise to aggressively fund its clinical development and pipeline expansion.…
RVMD
Revolution Medicines, Inc. Common Stock
$151.56
Related headlines
RVMD 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Revolution Medicines, Inc. Common Stock's 12-month outlook, with a consensus price target around $197.03 and implied upside of +30.0% versus the current price.
Average Target
$197.03
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$121 - $197
Analyst target range
Analyst coverage is robust with 13 firms providing estimates, and the institutional sentiment is overwhelmingly bullish, as evidenced by a series of 'Buy', 'Outperform', or 'Overweight' ratings from major firms including Wells Fargo, Needham, Piper Sandler, JP Morgan, and RBC Capital in early 2026. The consensus recommendation is a 'Buy', with no recent downgrades noted. The average analyst target price is not explicitly provided in the data, but the estimated EPS average is $9.23, though applying a forward P/E is not feasible given the lack of profitability. The implied upside must be calculated from a consensus price target, which is not available in the dataset; however, the uniform bullish ratings and the stock's reaction to positive news suggest strong analyst conviction. The target price range, as inferred from the wide dispersion in revenue estimates (low of $1.45B to high of $13.98B), signals high uncertainty regarding the commercial potential and timing of daraxonrasib's approval and launch. The high-end targets likely assume best-case commercial uptake, expansion into additional indications, and minimal competitive threats, while the low-end targets may factor in delays, narrower labels, or pricing pressures. The recent capital raise has addressed near-term dilution and financing risk, which may have solidified analyst confidence, as reflected in the maintained positive ratings post-offering.
Bulls vs Bears: RVMD Investment Factors
The bull case for Revolution Medicines is currently stronger, anchored by the transformative Phase 3 survival data for daraxonrasib and the subsequent $2.2 billion capital raise that de-risks the financial runway. These are concrete, company-specific catalysts that have driven a fundamental re-rating. However, the bear case presents severe risks centered on valuation, as the stock's $15.1 billion market cap prices in near-perfect execution with no margin for error. The single most important tension in the investment debate is between the validated, high-potential science and the extreme valuation that leaves the stock exposed to catastrophic downside if commercial expectations are not met. The stock is a binary bet on daraxonrasib's success, making it a high-risk, high-reward proposition.
Bullish
- Transformative Phase 3 Survival Data: The lead candidate daraxonrasib demonstrated a survival benefit in a Phase 3 pancreatic cancer trial, a notoriously difficult-to-treat indication. This data is the primary driver of the stock's 290.62% one-year return and validates the company's scientific platform, significantly de-risking the path to regulatory approval and commercialization.
- Massive $2.2B Capital Raise Secures Runway: The concurrent public offerings in April 2026 raised approximately $2.2 billion, fundamentally altering the financial profile. This capital eliminates near-term financing risk, providing ample resources to fund aggressive clinical development of daraxonrasib and the broader pipeline through key milestones without shareholder dilution concerns for the foreseeable future.
- Overwhelmingly Bullish Analyst Sentiment: All 13 covering analysts maintain 'Buy', 'Outperform', or 'Overweight' ratings, reflecting strong institutional conviction in the company's prospects post-Phase 3 data. This consensus, from firms like Wells Fargo and JP Morgan, provides a supportive backdrop and suggests limited near-term downside from analyst downgrades.
- Dominant Position in High-Value Oncology Target: As a leader in developing RAS(ON) inhibitors for RAS-addicted cancers, Revolution Medicines is targeting a historically undruggable genetic driver with a massive market opportunity. Analyst revenue estimates average $5.43 billion, with a high-end projection of nearly $14 billion, underscoring the transformative commercial potential priced into the stock.
Bearish
- Extreme Valuation with No Current Revenue: The company has zero product revenue, making traditional valuation metrics (P/S, P/E) meaningless. The $15.1 billion market cap is a pure bet on future success, with the price-to-book ratio soaring to 9.28. This leaves the stock vulnerable to severe multiple compression on any clinical or commercial setback.
- Sustained and Escalating Operating Losses: Net losses widened from -$194.6M in Q4 2024 to -$364.9M in Q4 2025, driven by R&D expenses of $292.6M. While the capital raise funds this burn, it underscores the binary, high-risk nature of the investment where value is contingent on future commercialization success, not current financial performance.
- High Beta and Volatility Risk: With a beta of 1.413, RVMD is approximately 41% more volatile than the broader market. This is evidenced by a 24.95% max drawdown and the sharp price swings around clinical news. Such volatility demands a high risk tolerance and makes the stock unsuitable for conservative investors.
- Commercial Execution and Competition Risks: Future success hinges on flawless execution of regulatory filings, launch, and market penetration in a competitive oncology landscape. The wide dispersion in analyst revenue estimates ($1.45B low to $13.98B high) reflects high uncertainty around pricing, market share, and potential competitive entrants targeting the same biology.
RVMD Technical Analysis
The stock is in a powerful, sustained long-term uptrend, evidenced by its staggering 290.62% one-year price change, significantly outpacing the SPY's 27.88% return. As of the latest close of $151.56, the price is trading near the top of its 52-week range, approximately 97% of the way from the 52-week low of $34.00 to the high of $156.25, indicating strong momentum but also potential overextension. The stock has experienced significant volatility, with two major step-ups in price: a surge from ~$80 to ~$120 in early January 2026, and a more dramatic jump from ~$96 to over $150 in mid-April 2026 following pivotal clinical data and a capital raise.
Recent momentum remains robust, with a 48.84% gain over the past three months and a 7.11% gain over the past month, both significantly outperforming the broader market (SPY up 8.15% and 4.84%, respectively). This suggests the positive momentum from the April catalyst has been sustained, though the stock has entered a consolidation phase around the $140-$155 level following the initial spike. The beta of 1.413 confirms the stock is approximately 41% more volatile than the market, which is typical for a clinical-stage biotech but demands careful risk management. Key technical support is now established around the $135-$140 zone, which was the initial post-news consolidation area in late April, while the 52-week high of $156.25 serves as immediate resistance. A decisive breakout above $156.25 would signal a continuation of the uptrend and potentially target new highs, while a breakdown below the $135 support could indicate profit-taking and a retest of the $120 level. The stock's high beta and recent price history suggest it is highly sensitive to company-specific news flow, and position sizing should account for this elevated volatility.
Beta
1.41
1.41x market volatility
Max Drawdown
-24.9%
Largest decline past year
52-Week Range
$34-$156
Price range past year
Annual Return
+290.6%
Cumulative gain past year
| Period | RVMD Return | S&P 500 |
|---|---|---|
| 1m | +7.1% | +4.4% |
| 3m | +48.8% | +9.3% |
| 6m | +113.9% | +10.5% |
| 1y | +290.6% | +28.8% |
| ytd | +91.8% | +9.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RVMD Fundamental Analysis
As a pre-revenue clinical-stage biotech, Revolution Medicines has no product sales; its quarterly revenue is $0, with only minimal collaboration revenue of $7.0 million reported historically. The company's growth trajectory is purely a function of clinical pipeline progression, with the recent Phase 3 success for daraxonrasib representing the primary value inflection point. The multi-quarter trend shows escalating operating losses as R&D investments intensify, with net loss widening from -$194.6 million in Q4 2024 to -$364.9 million in Q4 2025, reflecting the substantial costs of advancing a late-stage oncology pipeline. The company is deeply unprofitable, with a gross profit of -$4.7 million in the latest quarter (due to cost of revenue from collaboration agreements) and a net loss margin that is not calculable on zero revenue. Operating expenses, dominated by Research & Development which was $292.6 million in Q4 2025, are the primary driver of losses. Margin analysis on profitability is not applicable; the key metric is the burn rate and the path to future commercialization, which the recent $2.2 billion capital raise is designed to fund. The balance sheet and cash flow picture has been fundamentally altered by the April 2026 capital raise, which is not yet fully reflected in the latest quarterly statements ending December 2025. Prior to the raise, the company was burning substantial cash, with operating cash flow of -$274.2 million and free cash flow of -$276.2 million in Q4 2025. The debt-to-equity ratio is a low 0.097, indicating minimal leverage, and the current ratio is a robust 7.14, signaling strong short-term liquidity. The massive equity offering significantly de-risks the financial runway, providing ample capital to fund operations through key clinical milestones without near-term financing needs.
Quarterly Revenue
$0.0B
2025-12
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-913731000.0B
Last 12 Months
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RVMD Overvalued?
Given the company's negative net income of -$364.9 million and negative EBITDA of -$348.3 million, traditional earnings-based multiples are not meaningful. Therefore, the primary valuation metric is the Price-to-Sales (P/S) ratio, which is also not calculable (0) due to the absence of revenue. In the absence of sales, the market is valuing the company based on its pipeline potential and future revenue projections, as evidenced by its $15.1 billion market cap. Analyst estimates point to significant future revenue potential, with an average estimate of $5.43 billion, though the range is wide from $1.45 billion to $13.98 billion. Peer comparison for a clinical-stage biotech with a breakthrough asset in a major oncology indication is challenging, but the valuation is implicitly a premium on the potential market opportunity for its RAS inhibitors. The absence of a calculable P/S or EV/Sales ratio against industry averages underscores the binary, event-driven nature of the valuation, which is based on the probability of regulatory success and commercial peak sales. Historically, the stock's valuation multiples have expanded dramatically alongside its share price appreciation and clinical progress. For instance, the price-to-book ratio has risen from around 2.2 in late 2023 to 9.28 as of the latest data, reflecting a massive re-rating based on reduced clinical risk and future cash flow expectations. The current valuation near all-time highs suggests the market is pricing in a high probability of success and significant future revenue, leaving little margin for clinical or regulatory setbacks.
PE
-13.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -22x~-6x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-13.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are dominated by the company's pre-revenue status and escalating cash burn. With quarterly net losses widening to -$364.9 million and R&D expenses of $292.6 million in Q4 2025, the business model is entirely dependent on converting clinical success into future revenue. The recent $2.2 billion raise mitigates liquidity risk but does not change the fundamental operational risk of clinical trial failures, regulatory delays, or manufacturing issues. Revenue concentration risk is absolute, as the entire valuation hinges on daraxonrasib, with no diversified product sales to cushion any pipeline setback.
Market & Competitive Risks are severe due to the stock's premium valuation and event-driven nature. Trading at a price-to-book ratio of 9.28, far above historical levels, the stock is highly susceptible to valuation compression if growth stock multiples contract or if the clinical narrative falters. The beta of 1.413 confirms high sensitivity to market swings and sector rotations out of biotech. Competitive risks are latent but potent, as major pharmaceutical companies are actively pursuing RAS pathway inhibitors, as evidenced by Merck's recent $6.7 billion acquisition of Terns Pharmaceuticals, which could accelerate rival programs.
Worst-Case Scenario involves a material clinical or regulatory setback for daraxonrasib, such as an unexpected safety issue in ongoing trials or a Complete Response Letter from the FDA. This would shatter the growth narrative, trigger massive analyst downgrades, and lead to a rapid derating. Given the stock's reliance on future potential, a realistic downside could see it retreat towards its pre-catalyst trading range and 52-week low of $34.00, representing a potential loss of over -77% from the current price of $151.56. A more immediate adverse scenario, involving a breakdown of technical support, could see a -21% decline to the $120 level in the near term.